A Phase 3 interventional study of Adalimumab in Ulcerative Colitis, sponsored by AbbVie. Completed at 16 sites in 6 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 10 in phase 3, and was the 12th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 152 across the 18 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
53 studies in Colitis, Ulcerative by AbbVie: 6 open now, 13 under way, 5 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2015, is one of 19 in phase 3, and was the 21st registered.
AbbVie’s Colitis, Ulcerative studies by the year they started, since 2000.
1 of the studies testing adalimumab in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Subject must have successfully enrolled and completed M11-290 study
Exclusion Criteria:
- Subject considered by the investigator, for any reason, to be an unsuitable candidate
Subjects receiving Adalimumab up to 288 weeks
Biological: Adalimumab
every other week or weekly subcutaneous injection
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 70 days following last dose of study drug (up to 298 weeks).
Proportion of Participants Who Achieve Clinical Remission as Measured by Partial Mayo Score (PMS)
The Partial Mayo Score (PMS) is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Physician's Global Assessment (PGA), scored from 0 (normal) to 3 (severe disease). The overall Partial Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1.
Time frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Proportion of Participants Who Achieve Clinical Response as Measured by PMS (From Study M11-290 Baseline)
The Partial Mayo Score (PMS) is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Physician's Global Assessment (PGA), scored from 0 (normal) to 3 (severe disease). The overall Partial Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical response was defined as a decrease in PMS ≥ 2 points and ≥ 30% from Study M11-290 Baseline.
Time frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Proportion of Participants Who Achieve Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission
The Pediatric Ulcerative Colitis Activity Index (PUCAI) measures UC disease activity in children and adolescents by evaluating the following 6 areas: abdominal pain, number of stools per day, stool consistency, amount of blood in stools, nocturnal stooling, and activity level. The PUCAI score ranges from 0 to 85 with higher scores representing more severe disease. Recommended cut-off scores to differentiate disease activity are 0-9 (inactive), 10-34 (mild), 35-64 (moderate), and \> 65 (severe). Clinical remission was defined as a PUCAI score \< 10.
Time frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Proportion of Participants Who Achieve PUCAI Response (From Study M11-290 Baseline)
The Pediatric Ulcerative Colitis Activity Index (PUCAI) measures UC disease activity in children and adolescents by evaluating the following 6 areas: abdominal pain, number of stools per day, stool consistency, amount of blood in stools, nocturnal stooling, and activity level. The PUCAI score ranges from 0 to 85 with higher scores representing more severe disease. Recommended cut-off scores to differentiate disease activity are 0-9 (inactive), 10-34 (mild), 35-64 (moderate), and \> 65 (severe). PUCAI response was defined as a decrease in PUCAI score ≥ 20 points from Study M11-290 Baseline.
Time frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
| Milestone | Adalimumab |
|---|---|
| Started | 59 |
| Completed | 28 |
| Not completed | 31 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Lack of efficacy | 18 |
| Withdrew: Required alternative (or prohibited) therapy | 1 |
| Withdrew: Subject noncompliance | 3 |
| Withdrew: Other | 2 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| Participants | Adalimumab |
|---|---|
| Any TEAE | 55 |
| TESAE | 15 |
The Partial Mayo Score (PMS) is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Physician's Global Assessment (PGA), scored from 0 (normal) to 3 (severe disease). The overall Partial Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1.
| Participants | Adalimumab |
|---|---|
| Week 4 | 50 |
| Week 8 | 47 |
| Week 12 | 51 |
| Week 24 | 43 |
| Week 36 | 45 |
| Week 48 | 40 |
| Week 60 | 42 |
| Week 72 | 42 |
| Week 84 | 40 |
| Week 96 | 36 |
| Week 108 | 37 |
| Week 120 | 33 |
| Week 144 | 32 |
| Week 168 | 31 |
| Week 192 | 30 |
| Week 216 | 29 |
| Week 240 | 28 |
| Week 264 | 27 |
| Week 288 | 25 |
The Partial Mayo Score (PMS) is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Physician's Global Assessment (PGA), scored from 0 (normal) to 3 (severe disease). The overall Partial Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical response was defined as a decrease in PMS ≥ 2 points and ≥ 30% from Study M11-290 Baseline.
| Participants | Adalimumab |
|---|---|
| Week 4 | 56 |
| Week 8 | 55 |
| Week 12 | 56 |
| Week 24 | 51 |
| Week 36 | 50 |
| Week 48 | 47 |
| Week 60 | 46 |
| Week 72 | 44 |
| Week 84 | 43 |
| Week 96 | 42 |
| Week 108 | 40 |
| Week 120 | 39 |
| Week 144 | 35 |
| Week 168 | 35 |
| Week 192 | 32 |
| Week 216 | 30 |
| Week 240 | 29 |
| Week 264 | 28 |
| Week 288 | 26 |
The Pediatric Ulcerative Colitis Activity Index (PUCAI) measures UC disease activity in children and adolescents by evaluating the following 6 areas: abdominal pain, number of stools per day, stool consistency, amount of blood in stools, nocturnal stooling, and activity level. The PUCAI score ranges from 0 to 85 with higher scores representing more severe disease. Recommended cut-off scores to differentiate disease activity are 0-9 (inactive), 10-34 (mild), 35-64 (moderate), and \> 65 (severe). Clinical remission was defined as a PUCAI score \< 10.
| Participants | Adalimumab |
|---|---|
| Week 4 | 50 |
| Week 8 | 46 |
| Week 12 | 50 |
| Week 24 | 42 |
| Week 36 | 44 |
| Week 48 | 39 |
| Week 60 | 38 |
| Week 72 | 42 |
| Week 84 | 40 |
| Week 96 | 37 |
| Week 108 | 37 |
| Week 120 | 34 |
| Week 144 | 33 |
| Week 168 | 30 |
| Week 192 | 28 |
| Week 216 | 28 |
| Week 240 | 27 |
| Week 264 | 26 |
| Week 288 | 24 |
The Pediatric Ulcerative Colitis Activity Index (PUCAI) measures UC disease activity in children and adolescents by evaluating the following 6 areas: abdominal pain, number of stools per day, stool consistency, amount of blood in stools, nocturnal stooling, and activity level. The PUCAI score ranges from 0 to 85 with higher scores representing more severe disease. Recommended cut-off scores to differentiate disease activity are 0-9 (inactive), 10-34 (mild), 35-64 (moderate), and \> 65 (severe). PUCAI response was defined as a decrease in PUCAI score ≥ 20 points from Study M11-290 Baseline.
| Participants | Adalimumab |
|---|---|
| Week 4 | 47 |
| Week 8 | 47 |
| Week 12 | 49 |
| Week 24 | 42 |
| Week 36 | 43 |
| Week 48 | 38 |
| Week 60 | 39 |
| Week 72 | 40 |
| Week 84 | 37 |
| Week 96 | 37 |
| Week 108 | 36 |
| Week 120 | 34 |
| Week 144 | 32 |
| Week 168 | 30 |
| Week 192 | 27 |
| Week 216 | 25 |
| Week 240 | 26 |
| Week 264 | 23 |
| Week 288 | 21 |
Collected over All-cause mortality were reported from enrollment up to 298 weeks, median time on follow up (median time subjects were followed) was 1723.0 days for adalimumab. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 70 days after the last dose of study drug; mean duration on study drug was 1354.2 days for adalimumab.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | 0/59 (0%) | 16/59 (27.1%) | 54/59 (91.5%) |
| Event | Adalimumab |
|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 5/59 |
| ANAEMIABlood and lymphatic system disorders | 2/59 |
| LARGE INTESTINE POLYPGastrointestinal disorders | 2/59 |
| BLOOD LOSS ANAEMIABlood and lymphatic system disorders | 1/59 |
| DYSPEPSIAGastrointestinal disorders | 1/59 |
| RECTAL HAEMORRHAGEGastrointestinal disorders | 1/59 |
| CHOLECYSTITISHepatobiliary disorders | 1/59 |
| BRONCHITISInfections and infestations | 1/59 |
| LATENT TUBERCULOSISInfections and infestations | 1/59 |
| LYMPH NODE ABSCESSInfections and infestations | 1/59 |
| Event | Adalimumab |
|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 20/59 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 16/59 |
| NASOPHARYNGITISInfections and infestations | 13/59 |
| COVID-19Infections and infestations | 10/59 |
| MYCOBACTERIUM TUBERCULOSIS COMPLEX TEST POSITIVEInvestigations | 10/59 |
| HEADACHENervous system disorders | 9/59 |
| PHARYNGITISInfections and infestations | 8/59 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 8/59 |
| ANAEMIABlood and lymphatic system disorders | 7/59 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 6/59 |
Integrated Full Analysis Set (IFAS) included all enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Adalimumab |
|---|---|
| Mean | 14.7 ± 3.26 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 30 |
| Male | 29 |
| Ethnicity (NIH/OMB)(Participants) | Adalimumab |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 4 |
| Unknown or Not Reported | 54 |
| Race (NIH/OMB)(Participants) | Adalimumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 52 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Proportion of Participants with Partial Mayo Score (PMS) Remission at Baseline(Participants) | Adalimumab |
|---|---|
| Count of participants | 46 |
| Proportion of Participants with PMS Response at Study M11-290 Baseline(Participants) | Adalimumab |
|---|---|
| Count of participants | 54 |
| Proportion of Participants Who Achieve PUCAI Remission at Baseline(Participants) | Adalimumab |
|---|---|
| Count of participants | 42 |
| Proportion of Participants Who Achieve PUCAI Response at Study M11-290 Baseline(Participants) | Adalimumab |
|---|---|
| Count of participants | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Nov 2015 to primary completion in Apr 2025, 112 months.
Results were first posted in Oct 2025, 6 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 112 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab